Month: June 2025

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering. J.P. Morgan, Morgan Stanley, Guggenheim Securities and Cantor...

CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced the execution of an amended credit facility with Wells Fargo Bank, NA (“Wells Fargo”). This amendment modifies the current facility extending the term of the agreement to December 31, 2026 and modifies the borrowing capacity to $10 million. Mark A. Le Doux, Chairman and Chief Executive Officer of NAI stated, “We are grateful for our long-standing relationship with Wells Fargo and we believe this amended credit facility is made possible by the strength of our balance sheet. We believe this facility will be sufficient to support our working capital needs as we continue to strive towards continued top-line...

ELKHART, Ind., June 23, 2025 (GLOBE NEWSWIRE) — THOR Industries, Inc. (NYSE: THO) today announced that its Board of Directors has retired the Company’s existing share repurchase authorization which was set to expire on July 31, 2025 and re-authorized the Company to repurchase up to $400 million of its Common Stock.  The Company may purchase shares on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means. The timing and amount of any transactions will be at the Company’s discretion subject to the market price of the stock, general market and economic conditions, cash availability, applicable legal requirements, and other growth investment opportunities. The repurchase authorization will expire July 31, 2027. “I am pleased to announce that THOR’s...

Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E. Martin Brenner, DVM, Ph.D., iBio’s CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic...

BETHESDA, MD, June 23, 2025 (GLOBE NEWSWIRE) — Alset Inc. (NASDAQ:AEI) (“AEI” or the “Company”), a diversified holding company principally engaged through its subsidiaries in the development of smart and sustainable home communities and other property development, financial services, digital transformation technologies, biohealth activities and consumer products, is pleased to announce that its Board of Directors has authorized a new stock repurchase program of up to $1,000,000 of the Company’s outstanding common stock. Repurchases under the program may be made through December 31, 2025, or until the authorized amount has been fully utilized, whichever occurs first. The Company has authorized its broker to implement this repurchase program and agreed that such broker will have complete discretion and control...

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) — (TSX: BAAA, BAAA.U) Brompton Funds announces distributions for Brompton Wellington Square AAA CLO ETF payable on July 15, 2025 to unitholders of record at the close of business on June 30, 2025 as follows:Ticker Amount Per Unit  BAAA Cdn$0.086  BAAA.U US$0.08722       About Brompton FundsFounded in 2000, Brompton is an experienced investment fund manager with income and growth focused investment solutions including TSX traded closed-end funds and exchange-traded funds. For further information, please contact your investment advisor, call Brompton’s investor relations line at 416-642-6000 (toll-free at 1-866-642-6001), email info@bromptongroup.com or visit our website at www.bromptongroup.com. About Wellington SquareWellington Square Advisors Inc. (“Wellington Square”) is...

FREEHOLD, NJ, June 23, 2025 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced that it will host its Second Quarter 2025 Financial Results Webcast and Conference Call. Senior management will discuss the results, current market conditions and future outlook on Thursday, August 7, 2025, at 10:00 a.m. Eastern Time. UMH’s Second Quarter 2025 results will be released on Wednesday, August 6, 2025, after the close of trading on the New York Stock Exchange and will be available on the Company’s website at www.umh.reit, in the Financials section. To participate in the webcast, select the webcast icon on the homepage of the Company’s website at www.umh.reit, in the Upcoming Events section. Interested parties can also participate via...

Pending a decision from the European Commission, Ozempic® (once-weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist (GLP-1 RA) class, demonstrating improvements in blood sugar, weight, cardiovascular (CV) events, chronic kidney disease and peripheral arterial disease (PAD) functional outcomes1. Ozempic® is the first and only glucose-lowering treatment with proven functional benefits in people with type 2 diabetes and PAD1. The positive opinion is based on results from the phase 3b STRIDE trial, which demonstrated an improvement in walking capacity in patients with type 2 diabetes and PAD1. Additional data from STRIDE and SOUL (CV outcomes with Rybelsus® in type 2 diabetes) were presented today at the American Diabetes Association’s (ADA) 85th Scientific Sessions2,3.Bagsværd, Denmark,...